Clinical studies recruiting near Oldenburg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · ohO Research GmbH · Pfizer · NCT06758401 REscue Stenting With CREDO® Heal for Recanalisation After Unsuccessful Thrombectomy (RECHRUT)
Phase N/A · Institut für Radiologie und Neuroradiologie, Evangelisches K · Acandis GmbH · NCT05345483 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Pius Hospital Oldenburg · Hoffmann-La Roche · NCT06793215 Perturbation-Based Treadmill Training to Prevent Unrecovered Falls in Geriatric Patients
NA · Carl von Ossietzky Universität, Department für Versorgungsfo · University of Oldenburg · NCT06652828 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Red-Institut GmbH · Amgen · NCT07037433 A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chr
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT07549516 A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277 A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Dia
Phase 3 · RED-Institut GmbH · Eli Lilly and Company · NCT07222332 A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Phase 3 · RED-Institut GmbH · Eli Lilly and Company · NCT07369011 International HIT-MED Registry (I-HIT-MED)
Phase N/A · Klinikum Oldenburg · Universitätsklinikum Hamburg-Eppendorf · NCT02417324 Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Seve
Phase N/A · Klinikum Oldenburg · Esteve Pharmaceuticals, S.A. · NCT00903110 PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · Onkologische Praxis Oldenburg, Gemeinschaftspraxis für Inner · Women's Cancer Study Group GmbH · NCT05792150 GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of
Phase N/A · Klinikum Oldenburg · Goethe University · NCT02872987 The DefiPace Study
Phase N/A · Oldenburg Hospital AöR / Medical Campus University of Oldenb · Institut für Pharmakologie und Präventive Medizin · NCT04804748 A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung C
Phase 3 · Pius Hospital Oldenburg ( Site 1407) · Merck Sharp & Dohme LLC · NCT06623422 Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNS
Phase 3 · Pius-Hospital Oldenburg · University Hospital Freiburg · NCT06830421 DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · Pius-Hospital, Oldenburg · Boehringer Ingelheim · NCT07472517 A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06830720 A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed No
Phase 3 · Pius Hospital, University Medicine Oldenburg · ETOP IBCSG Partners Foundation · NCT06931717 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Im
Phase 1/Phase 2 · ohO Research GmbH /ID# 273060 · AbbVie · NCT06772623 Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
Phase 2 · Klinikum Oldenburg, Universitätsklinik für Anästhesiologie/ · Artcline GmbH · NCT05442710 Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Le
Phase 2 · Klinikum Oldenburg AöR, Universitätsklinik für Innere Medizi · Goethe University · NCT06648889 A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · Pius-Hospital Oldenburg · Daiichi Sankyo · NCT06203210 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Phase 3 · Klinikum Oldenburg · University of Heidelberg Medical Center · NCT06216158 Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06947993 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3 · Klinikum Oldenburg AöR, Zentrum für Kinder- und Jugendmedizi · University Hospital Muenster · NCT04043494 Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressur
Phase 3 · Red-Institut GmbH · Amgen · NCT07226765 Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic N
Phase 3 · Research Site · AstraZeneca · NCT07291037 Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3 · Klinikum Oldenburg gGmbH, Zentrum für Kinder- u. Jugendmediz · Martin Schrappe · NCT03643276 A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Phase 3 · RED-Institut GmbH · Eli Lilly and Company · NCT07282600

Look up another city

Look up another condition